TF
REGN icon

Tompkins Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Tompkins Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.11K Buy
+13
New +$8.85K ﹤0.01% 469
2025
Q2 		– Sell
-50
Closed -$31.7K – 570
2025
Q1 		$31.7K Buy
+50
New +$34.4K ﹤0.01% 365
2021
Q4 		– Sell
-15
Closed -$9K – 389
2021
Q3 		$9K Buy
+15
New +$9.31K ﹤0.01% 328
2021
Q1 		$7K Hold
15
– – ﹤0.01% 378
2020
Q4 		$7K Buy
+15
New +$8.1K ﹤0.01% 385
2014
Q1 		– Sell
-91
Closed -$25K – 537
2013
Q4 		$25K Hold
91
– – 0.01% 337
2013
Q3 		$28K Buy
+91
New +$23.9K 0.01% 319

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Tompkins Financial's REGN Position: Q2 2026 in Review

Tompkins Financial opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 13 shares worth $8.11K. The stake represents ﹤0.01% of the portfolio and ranks #469 among its holdings. This is a return to the name: Tompkins Financial previously reported a position in REGN as recently as Q1 2025.

Tompkins Financial first reported a position in REGN in Q3 2013 and has held it in 7 quarters since. The position peaked at $31.7K in Q1 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Tompkins Financial held 13 shares of Regeneron Pharmaceuticals worth $8.11K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Tompkins Financial position in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Tompkins Financial's portfolio in Q2 2026, its #469 holding.
  • Tompkins Financial first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 7 quarters since.
  • Tompkins Financial's Regeneron Pharmaceuticals position peaked at $31.7K in Q1 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Tompkins Financial's 13F filing for Q2 2026, filed 15 Jul 2026.